Advice
following a full submission:
boceprevir (Victrelis®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy.
In the pivotal phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV, who had failed previous therapy, increased the proportion of patients who achieved a sustained virologic response.
Download detailed advice198KB (PDF)
Medicine details
- Medicine name:
- boceprevir (Victrelis) Experienced Patients
- SMC ID:
- 722/11
- Indication:
- Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy.
- Pharmaceutical company
- MSD
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2011